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I. Introduction 
 
Synovial sarcoma is an aggressive soft tissue tumor with possibly mesenchymal 
stem cell origin. It is also a well-known “translocation-associated tumor” with 
characteristic t(X;18) (p11.2;q11.2), represented in more than 95% of the cases. SYT 
functions as a transcription coactivator containing an SNH domain which interacts with 
SWI/SNF ATPase-associated chromatin remodeling complex and transcription factors 
such as AF10 whereas SSX acts as a transcription corepressor containing an SSXRD 
which interacts with polycomb group. The SYT-SSX fusion protein, which retains 
almost the entire SYT including SNH with losing the last 8 amino acids at the 
N-terminal side and replaced by the last 78 amino acids of SSX containing SSXRD. By 
activating and silencing of the target genes epigenetically, the fusion protein causes 
general alteration of cellular programming. The prognosis varies between 36 to 76% of 
5-year survival rate and the prognostic factors (size, age, mitoses and 
poorly-differentiated areas) are also poorly defined indicating the need of identifying 
new markers.  
Controversies exist among the ploidy, karyotype regarding the prognosis; on the 
other hand, EZH2 is a core member of the polycomb repressing complex 2 (PRC2) 
which functions as a histone methyltransferase by producing a characteristic H3K27me3 
epigenetic mark. It plays an important role in cell cycle regulation, DNA damage repair, 
cell differentiation, senescence, and apoptosis. EZH2 overexpression has been found in 
many tumors including carcinomas and lymphomas and it is associated with aggressive 
clinical behavior. However, EZH2 in soft tissue sarcomas are rarely been discussed and 
its expression profile and the clinical relevance in particularly in synovial sarcomas, are 
still largely unknown. 
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II. Objective 
 
My work was divided in two parts; the first part was to establish the correlation 
among the ploidy, karyotypic complexity regarding the clinical outcome. The second 
part was to investigate the relevance of EZH2 in synovial sarcomas. I summarized as 
follow 
1. To investigate the DNA ploidy using image cytometry with fine-tune interpretation 
and correlates the result with high-resolution comparative genomic hybridization 
(HR-CGH) and clinical outcome.  
2. To investigate the utility of EZH2 as a diagnostic marker in synovial sarcomas by 
comparing its expression (both in mRNA and protein levels) cross the histological 
subtypes, the molecular features and clinical data. 
3. To elucidate the functional correlation between EZH2 and its epigenetic marker, 
H3K27me3. 
4. To investigate the impact of EZH2 expression, along with H3K27me3 and Ki-67, on 
overall survival based on Kaplan-Meier curve. 
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III. Materials and Methods 
 
Fifty-five primary tumors without preoperative chemoradiotherapy were selected 
including 6 poorly differentiated (PDSS)-, 39 monophasic (MPSS)-, and 10 biphasic 
(BPSS) - synovial sarcomas, respectively in FFPE state. 9 cases fresh frozen samples 
containing 2 PDSS, 4 MPSS and 3 BPSS were also available for HR-CGH analysis. 
Image cytometry was performed with the help of Feulgen stain and histogram was 
generated after measuring 30 reference- and 200 tumor- cells, respectively. Aneuploidy 
was identified when abnormal stem line was found, whereas the complex- or simple- 
diploidy was defined by the presence or absence of cells harbored “5c-exceeding 
events”. Meanwhile, HR-CGH was also performed on the selected 9 cases and both 
positive and negative controls were also used. The result of ploidy, karyotype and the 
clinical outcome were correlated. 
Tissue microarrays were created from those 55 cases and immunostained with 
EZH2, H3K27me3 and Ki-67 and evaluated by pre-established scoring criteria. Results 
of the three immunostainings were compared, and differences were sought between the 
histological subtypes as well as patient groups defined by gender, age, tumor size, tumor 
location, the presence of distant metastasis, and the type of fusion gene. Quantitative 
real-time PCR was also performed to detect the EZH2 expression in mRNA level as 
well to correlate the protein level. The relationship between EZH2 expression and 
survival was plotted on a Kaplan-Meier curve. 
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IV. Results 
 
IV.1 Significant differences among aneuploid, simple diploid and complex diploid 
groups 
Ten-, 12- and 33- cases of aneuploidy-, complex diploid- and simple diploid- 
group were identified by image cytometry, respectively.  
In HR-CGH analysis; the aneuploid group contained a large number of genetic 
alterations with the sum gain of at least 2 chromosomes; the complex diploid group 
showed substantial but less aberrations whereas the simple diploid one, the 
chromosomal aberrations were hardly detectable.  
Eighty percent, 50% and 39% of aneuploidy-, complex diploid- and simple 
diploid- group developed metastasis, respectively. By using Fisher’s exact test the three 
groups proved to be significantly different. 
 
IV.2 High expression of EZH2 and high abundance of H3K27me3 in PDSS 
High expression of EZH2 mRNA and protein levels was specifically detected in 
the PDSS. EZH2 scores were found to correlate with those of Ki-67 and H3K27me3 
indicating high EZH2 expression is associated with higher mitotic activity and the 
functional participation of PRC2, respectively.  
 
IV.3 EZH2 as a potential prognostic marker in synovial sarcoma 
Cross all subtypes; cases with high EZH2 score were characterized by larger tumor 
size (≥ 5cm), distant metastasis, and poor prognosis. Such association hold true without 
PDSS implying in the MPSS and BPSS; higher expression of EZH2 was associated with 
higher proliferation rate, larger tumor size, and the risk of developing early distant 
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metastasis. In these histological groups, EZH2 was superior to Ki-67 in predicting 
tumor growth rate and distant metastasis. 
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V. Discussion 
 
Majority of synovial sarcomas, irrespective of the histological subtype, exhibit 
simple karyotypes additional to its specific t(X;18) translocation. Secondary genetic 
anomalies are sometimes seen, but these alterations are often variable and inconsistent. 
Measurement of the total DNA content gains high importance in estimating the 
prognosis of the disease in terms of the selection of the aggressiveness of the therapy. In 
the first part of my work; we were able to separate diploid synovial sarcoma in to 
complex diploid and simple diploid groups, respectively, which reflect distinct, 
karyotypic and prognostic features. Our result of image cytometry showed correlations 
with HR-CGH and the prognosis and it is regarded as fast, easy to perform and 
inexpensive tool which can be used as a screening method in diagnosed synovial 
sarcomas. 
On the other hand; although the pathomechanism in synovial sarcomas which lead 
to EZH2 up-regulation still need to be elucidated, the possible mechanism may due to 
Myc-associated up-regulation, induced by HIF1α and fusion protein or down-regulation 
of microRNAs. The overexpressed EZH2 may silence several target genes participating 
in apoptosis, mitosis, tumor-suppressing and angiogenesis which may lead to abnormal 
proliferation and aggressive behavior; it is important to establish the correlation 
between EZH2 and H3K27me3 since not all the tumors which show overexpressed 
EZH2 are always associated with its epigenetic mark. The reason may due to general 
down-regulation of PRC2-target genes, the formation of tumor-specific PRC2 which 
may have different substrate specificity, and also phosphorylation-induced conformation 
change, etc. High EZH2 status, in our investigation, was found to be predictive of fast 
tumor growth and distant metastasis in the MPSS+BPSS group which may explain the 
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variable clinical outcome even in the better differentiated synovial sarcomas. Thus, 
while not sufficiently specific when applied alone, EZH2 can be used as an auxiliary 
immunohistochemical marker of the poorly differentiated subtype in doubtful cases (e.g., 
better-differentiated histomorphology coupled with high mitotic rate, or vice versa). 
Moreover, EZH2 status, along with other our previously finding, the prognostic impact 
of ploidy, may refine the current stratification of MPSS and BPSS patients into low- and 
high-risk subgroups, thus influencing prognosis and possibly also the therapeutic 
strategies. 
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VI. Conclusions 
 
Our investigations showed consistent association between DNA ploidy, karyotypic 
complexity and also the clinical outcome. Study the epigenetic deregulation opens a 
new insight of oncogenesis of tumors; we are the first group investigating EZH2 
expression profile and the clinical relevance of synovial sarcomas. We summarized our 
results as following: 
1. Complex diploid group is associated with complex karyotype based on “single cell 
aneuploidy” phenomenon and has worse prognosis than simple diploid group.  
2. EZH2 can serve as diagnostic adjunct since its expression helps to distinguish 
PDSS from the MPSS and BPSS. Its overexpression is also associated with 
unfavorable clinical outcome. 
3. EZH2 expression correlates with H3K27me3 indicating functional participation of 
PRC2. 
4. High EZH2 expression can be a predictive marker in terms of fast tumor growth 
rate and early development of metastasis which are particularly useful in MPSS 
and BPSS. 
5. Both DNA ploidy and EZH2 expression have valuable prognostic impact in 
synovial sarcomas, since they offer complement data for clinicians in terms of 
patient management. EZH2 can also be the target for the epigenetic therapy, 
especially in combination with other epigenetic modulators and conventional 
chemotherapy to achieve maximized and synergetic effect.   
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